ClinicalTrials.gg
Not yet recruitingNCT06066866Updated Oct 6, 2023

Microbiome Sampling in GI Disease With a Focus on Small Intestinal Microbial Assessment

An observational study in Healthy, IBS - Irritable Bowel Syndrome and Inflammatory Bowel Diseases, sponsored by Stanford University. Not yet recruiting. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-06.

Sponsored by Stanford University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years to 100 Years
Sex
All
01

Study summary

GI disorders are influenced by the gut microbiome. To date, sampling of the small intestine in GI disorders has been limited. The investigators plan to sample the small intestinal contents during endoscopy for research purposes.

Read the detailed description

Current guidelines (AGA Clinical Practice Update, 2020) report the definition of SIBO as a clinical entity lacks precision and consistency; it is a term generally applied to a clinical disorder where symptoms, clinical signs, and/or laboratory abnormalities are attributed to changes in the numbers of bacteria or in the composition of the bacterial population in the small intestine. To date, there is unlimited knowledge regarding the diagnostic criterion which has been limited by nonspecific and nonsensitive testing such as breath tests. Breath tests have a limited use in patients with IBS-D who inherently have increased gut transit time rendering the testing invalid for accurately measuring small intestinal bacteria. Additionally, the relationship between SIBO and symptoms in patients without obvious risk factors (such as anatomical changes due to surgery) is unknown. The investigators study aims to investigate the microbial landscape of the small intestine in healthy patients and those with GI disease (suspected or diagnosed) undergoing an upper endoscopy by collecting an aspirate of patient small intestinal fluid and studying it.

02

Conditions studied

  • Healthy
  • IBS - Irritable Bowel Syndrome
  • Inflammatory Bowel Diseases
03

In context

Irritable Bowel Syndrome

1,121 studies on the registry are indexed under Irritable Bowel Syndrome; 212 are open to participants now.

This study's planned enrollment of 150 is close to the median of 161 across 192 observational studies indexed under Irritable Bowel Syndrome.

Browse Irritable Bowel Syndrome studies →

Lead sponsor

Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.

Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients seen at Stanford University Digestive Health Center who are scheduled for an upper endoscopy as part of their Standard Of Care

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18years
  • Patients seen at Stanford University Digestive Health Center who are scheduled for an upper endoscopy as part of their Standard Of Care

Exclusion criteria

Exclusion Criteria:

Children (under age 18years) Pregnant Women and Fetuses Neonates (0 - 28 days) Impaired Decision Making Capacity

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Interventions

  • Otherendoscopic sampling of luminal fluid

    We will collect luminal fluid via endoscopic sampling

06

What researchers measure

Primary outcomes

  1. Ability to isolate live bacteria from 95% of samples

    We aim to isolate live bacteria from 95% of samples

    Time frame: 1-4 years

Secondary outcomes

  1. Ability to measure quantitative Colony Forming Units (CFUs) in 90% of samples

    We aim to measure quantitative Colony Forming Units (CFUs) in 90% of samples

    Time frame: 1-4 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2024; primary completion for Jan 2026, 24 months later.

Of 52 non-industry observational studies under Irritable Bowel Syndrome, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 193. This study's planned 24 months is below that.

Counting every sponsor, half of 66 studies reached it within 42 months; a quarter within 21 and three quarters within 109.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2023
First posted
Oct 4, 2023
StartEst.
Jan 1, 2024
Primary completionEst.
Jan 1, 2026
CompletionEst.
Jan 1, 2028
Last update
Oct 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06066866
Responsible party
Sean Spencer (Instructor, Stanford Gastroenterology and Hepatology, Stanford University) — Principal investigator
First posted
Oct 4, 2023
Start date
Jan 1, 2024 (estimated)
Primary completion
Jan 1, 2026 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Oct 6, 2023

Study contacts

Sean P Spencer, MD,PhD
Contact
seanspen@stanford.edu
(650) 736-5555
Sean P Spencer, MD,PhD
principal investigator · Stanford University
Linda A Nguyen, MD
study chair · Stanford University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion